Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of advanced prostate cancer in men and uterine fibroids in women. To ensure the safety and efficacy… Read more













































Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of advanced prostate cancer in men and uterine fibroids in women. To ensure the safety and efficacy of this therapeutic agent, pharmaceutical laboratories rely on high-quality reference standards for comprehensive analytical testing and quality control. This category includes a broad array of impurities, degradation products, and stable isotope labelled compounds essential for rigorous impurity profiling and method validation. By utilizing these standardized materials, researchers can accurately identify, quantify, and characterize potential impurities that may arise during synthesis or storage, ensuring compliance with international regulatory guidelines. These analytical tools provide the precision required to support pharmaceutical development and routine monitoring, facilitating the development of robust assays for detecting and controlling drug-related components throughout the product lifecycle, from initial research to the assessment of finished dosage forms.